2 active not recruiting, 1 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Locally Advanced Unresectable Breast Carcinoma: new trials by email Literature Review of Locally Advanced Unresectable Breast Carcinoma trials Research Report on Locally Advanced Unresectable Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 89 | 2017-03-30 | 2026-08-28 |
| Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer Cyclophosphamide, Laboratory Biomarker Analysis, Veliparib - Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2011-05-02 | 2026-09-10 |
Breast Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Carcinosarcoma (1) · Endometrial Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
Breast Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Adenocarcinoma (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Squamous Cell (1) · DNA Virus Infections (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1)
Biopsy (2) · Cyclophosphamide (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · X-Rays (2) · Colony-Stimulating Factors (1) · Immunoglobulin G (1) · Phantoms, Imaging (1) · atezolizumab (1) · olaparib (1) · pembrolizumab (1) · sargramostim (1) · veliparib (1)
National Cancer Institute (NCI) (2) · Mayo Clinic (1)
United States (3)
Joseph A Sparano (1) · Patricia M LoRusso (1) · Yanyan Lou, MD, PhD (1)
N01CM62204 (1), P30CA013330 (1), UM1CA186644 (1), UM1CA186686 (1), UM1CA186688 (1), UM1CA186689 (1), UM1CA186691 (1), UM1CA186709 (1)